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To the Editor: The recently published article by Robinson
et al.,1 along with numerous other publications repeatedly
evaluating the relationship between hematocrit and patient
survival with different statistical analyses, has reached the
same conclusion: increased hematocrit is associated with
decreased mortality. Once again, hematocrit was used
implicitly as a surrogate end point for survival among end-
stage renal disease patients relying on epoetin treatment to
correct anemia, even though both clinical trial and observa-
tional data suggest that hematocrit may not be a valid
surrogate.2–4 We believe that it will be more interesting and
important if the authors would shift their focus from the
intermediate outcome (hematocrit) to the intervention
(epoetin treatment).
We appreciate the authors’ efforts in trying to examine a
causal link between anemia and survival by adjusting for
time-dependent hematocrit values and many comorbid
conditions that may contribute to epoetin resistance.
However, the causal effect of hematocrit must be evaluated
in the context of the particular intervention, specifically, the
level of epoetin dose. The authors controlled for the level of
epoetin dose in their Cox regression analyses, but they did
not report the impact of epoetin dose on survival. We can
infer from the clear inverse relationship between hematocrit
and epoetin dose that there will be a negative effect of higher
epoetin doses on patient survival, which is consistent with
our previously published findings.5 In fact, the independent
effect of epoetin dose on survival further confirms that the
observed association between hematocrit and survival should
not be interpreted as causal. It is time to investigate the direct
impact of epoetin, not just the intermediate outcome
(hematocrit), on the real clinical end point (survival).
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We thank Zhang and Thamer1 for their interest in our
article examining hemoglobin (Hb) level and mortality
among hemodialysis patients in the American arm of the
Dialysis Outcomes and Practice Patterns Study Phase I.2 To
reconcile in part the discrepancies between observational
studies examining achieved Hb levels and clinical trials
randomizing subjects to target Hb levels,3–6 we hypothe-
sized that the observational associations of higher Hb
levels with longer survival would be less apparent in our
Cox proportional hazards analysis accounting substantially
more comprehensively for potentially confounding mar-
kers of health status and delivered dialysis care than was
previously possible. As such, our goal was to examine the
association of Hb level, not epoetin dosing, with survival,
and Hb level was not a surrogate end point for survival,
but rather our primary exposure variable.
Contrary to our hypothesis, we found that Hb levels
o11 g/dl were associated with greater mortality than Hb
Z11 g/dl. Based on these and our other results, we
concluded that even after accounting for numerous
variables linked to mortality (including epoetin dosing or
not), anemia predicts mortality on hemodialysis overall
and among patient subgroups, and we raised the
possibility that the achievement of ‘near-normal’ Hb levels
may predict greater longer-term survival.
While our study provides these insights, unmeasured or
incompletely adjusted confounding remains a possible
explanation for our findings, and we took care to avoid
inferring a causal link between anemia and mortality on
the basis of our results. Zhang and Thamer suggest that
our data provide evidence that epoetin administration is
harmful, since subjects with higher Hb levels have both
lower epoetin doses and lower mortality. However,
attributing the association we found between Hb and
mortality to epoetin is an overinterpretation, as it is
possible that subjects with higher Hb levels would have
had lower mortality even had they not received lower
epoetin doses. Along with Zhang and Thamer, we call for
further investigation to elucidate the complex causal
relationships among anemia, epoetin, and parenteral iron
administered to treat anemia, changes in Hb level in
response to these treatments, and survival.
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